Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Luis Vinas

Plastic Surgery West Palm Beach, FL Medical Doctor

NPI 1871576579 CMS profile 176184

550 S Quadrille Blvd, Ste 100, West Palm Beach, FL 33401

Open in the dashboard

General payments

$32,401

63 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Luis Vinas of West Palm Beach, FL is reported in the CMS Open Payments database as having received $32,401 across 63 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $257 11
2024 General $67 3
2023 General $352 11
2022 General $358 6
2021 General $324 13
2020 General $28,789 10
2019 General $2,253 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Luis Vinas
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Luis Vinas were reported at $257. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Luis Vinas Plastic Surgery median Middle half National median
2019 $2,253 $371 $122–$1,483 $163
2020 $28,789 $158 $52–$438 $114
2021 $324 $249 $87–$752 $132
2022 $358 $274 $102–$793 $149
2023 $352 $299 $113–$891 $160
2024 $67 $361 $124–$1,062 $164
2025 $257 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $28,608 2 payments
  2. Mentor Worldwide LLC $1,786 24 payments
  3. Sientra, Inc. $671 1 payment
  4. Merz North America, Inc. $478 6 payments
  5. TELA Bio, Inc. $308 11 payments
  6. TEI Biosciences Inc $145 3 payments
  7. Integra LifeSciences Corporation $143 4 payments
  8. CooperSurgical, Inc. $52 2 payments
  9. Solta Medical, a division of Bausch Health US, LLC $43 2 payments
  10. Davol Inc. $32 1 payment
  11. Other $134 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Gift $29,945 2 payments
  2. Food and Beverage $2,456 61 payments
Products named General payments · program years 2019–2025
  1. BOTOX COSMETIC $28,585 1 payment
  2. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $671 1 payment
  3. MENTOR MemoryGel Resterilizable Gel Sizer $321 19 payments
  4. OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) $308 11 payments
  5. ARTOURA Breast Tissue Expander $237 14 payments
  6. Xeomin $196 4 payments
  7. SURGIMEND $145 3 payments
  8. MemoryGel Breast Implants $105 4 payments
  9. CODMAN CERTAS $77 1 payment
  10. CUSA CLARITY $77 1 payment
  11. Other $556 19 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

316

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$2,490

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

23.7%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tobramycin-Dexamethasone Tobramycin/Dexamethasone Brand 14 $714
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 61 $608
Mupirocin Generic 86 $571
Ciprofloxacin Hcl Generic 59 $329
Promethazine Hcl Generic 39 $107
Methylprednisolone Generic 13 $79
Alprazolam Generic 33 $42
Temazepam Generic 11 $39

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$13,825

Medicare's payments for the services billed

Medicare patients

25

Average age 75

Services billed

102

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 60%
Arthritis 44%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

63 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record